-
1
-
-
67650874081
-
Cancer statistics 2009
-
Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Thun, MJ. Cancer statistics 2009. CA Cancer J. Clin., 2009, 59 (4), 225-249.
-
(2009)
CA Cancer J. Clin
, vol.59
, Issue.4
, pp. 225-249
-
-
Jemal, A.1
Siegel, R.2
Ward, E.3
Hao, Y.4
Xu, J.5
Thun, M.J.6
-
2
-
-
16244403039
-
Cancer incidence and mortality in Europe 2004
-
Boyle, P.; Ferlay, J. Cancer incidence and mortality in Europe 2004. Ann. Oncol., 2005, 16(3), 481-488.
-
(2005)
Ann. Oncol
, vol.16
, Issue.3
, pp. 481-488
-
-
Boyle, P.1
Ferlay, J.2
-
3
-
-
70349847555
-
Ovarian cancer
-
Hennessy, BT.; Coleman, R.L.; Markman, M. Ovarian cancer. Lancet, 2009, 374(9698), 1371-1382.
-
(2009)
Lancet
, vol.374
, Issue.9698
, pp. 1371-1382
-
-
Hennessy, B.T.1
Coleman, R.L.2
Markman, M.3
-
4
-
-
0037102445
-
Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas
-
Schwartz, D.R.; Kardia, S.L.; Shedden, K.A.; Kuick, R.; Michailidis, G.; Taylor, J.M.; Misek, D.E.; Wu, R.; Zhai, Y.; Darrah, D.M.; Reed, H.; Ellenson, L.H.; Giordano, T.J.; Fearon, E.R.; Hanash, S.M.; Cho, K.R. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res., 2002, 62(16), 4722-4729.
-
(2002)
Cancer Res
, vol.62
, Issue.16
, pp. 4722-4729
-
-
Schwartz, D.R.1
Kardia, S.L.2
Shedden, K.A.3
Kuick, R.4
Michailidis, G.5
Taylor, J.M.6
Misek, D.E.7
Wu, R.8
Zhai, Y.9
Darrah, D.M.10
Reed, H.11
Ellenson, L.H.12
Giordano, T.J.13
Fearon, E.R.14
Hanash, S.M.15
Cho, K.R.16
-
5
-
-
2342592576
-
Carcinosarcoma of the ovary: 19 years of prospective data from a single center
-
Brown, E.; Stewart, M.; Rye, T.; Al-Nafussi, A.; Williams, A.R.; Bradburn, M.; Smyth, J.; Gabra, H. Carcinosarcoma of the ovary: 19 years of prospective data from a single center. Cancer, 2004, 100 (10), 2148-2153.
-
(2004)
Cancer
, vol.100
, Issue.10
, pp. 2148-2153
-
-
Brown, E.1
Stewart, M.2
Rye, T.3
Al-Nafussi, A.4
Williams, A.R.5
Bradburn, M.6
Smyth, J.7
Gabra, H.8
-
6
-
-
34249947772
-
Current management strategies for ovarian cancer
-
Aletti, G.D.; Gallenberg, M.M.; Cliby, W.A.; Jatoi, A; Hartmann, L.C. Current management strategies for ovarian cancer. Mayo Clin. Proc., 2007, 82(6), 751-770.
-
(2007)
Mayo Clin. Proc
, vol.82
, Issue.6
, pp. 751-770
-
-
Aletti, G.D.1
Gallenberg, M.M.2
Cliby, W.A.3
Jatoi, A.4
Hartmann, L.C.5
-
7
-
-
77951784627
-
Ovarian cancer pathogenesis: A model in evolution
-
Karst, A.M.; Drapkin, R. Ovarian cancer pathogenesis: a model in evolution. J. Oncol., 2010, 2010, 932371.
-
(2010)
J. Oncol
, vol.2010
, pp. 932371
-
-
Karst, A.M.1
Drapkin, R.2
-
8
-
-
65949104847
-
Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas
-
Kuo, K.T.; Guan, B.; Feng, Y.; Mao, T.L.; Chen, X.; Jinawath, N.; Wang, Y.; Kurman, R.J.; Shih, I.M., Wang, TL. Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer Res., 2009, 69(9), 4036-4042.
-
(2009)
Cancer Res
, vol.69
, Issue.9
, pp. 4036-4042
-
-
Kuo, K.T.1
Guan, B.2
Feng, Y.3
Mao, T.L.4
Chen, X.5
Jinawath, N.6
Wang, Y.7
Kurman, R.J.8
Shih, I.M.9
Wang, T.L.10
-
9
-
-
56749103412
-
The cell of origin of ovarian epithelial tumours
-
Dubeau, L. The cell of origin of ovarian epithelial tumours. Lancet Oncol., 2008, 9(12), 1191-1197.
-
(2008)
Lancet Oncol
, vol.9
, Issue.12
, pp. 1191-1197
-
-
Dubeau, L.1
-
11
-
-
34347347175
-
The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: Amorphologic and molecular genetic analysis
-
Dehari, R.; Kurman, R.J.; Logani, S; Shih, I.M. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: amorphologic and molecular genetic analysis. Am. J. Surg. Pathol., 2007, 31(7), 1007-1112.
-
(2007)
Am. J. Surg. Pathol
, vol.31
, Issue.7
, pp. 1007-1112
-
-
Dehari, R.1
Kurman, R.J.2
Logani, S.3
Shih, I.M.4
-
12
-
-
33846624310
-
Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship
-
Kindelberger, D.W.; Lee, Y.; Miron, A.; Hirsch, M.S.; Feltmate, C.; Medeiros, F.; Callahan, M.J.; Garner, E.O.; Gordon, R.W.; Birch, C.; Berkowitz, R.S.; Muto, M.G.; Crum C.P.Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am. J. Surg. Pathol., 2007, 31(2), 161-169.
-
(2007)
Am. J. Surg. Pathol
, vol.31
, Issue.2
, pp. 161-169
-
-
Kindelberger, D.W.1
Lee, Y.2
Miron, A.3
Hirsch, M.S.4
Feltmate, C.5
Medeiros, F.6
Callahan, M.J.7
Garner, E.O.8
Gordon, R.W.9
Birch, C.10
Berkowitz, R.S.11
Muto, M.G.12
Crum, C.P.13
-
13
-
-
33846187651
-
A candidate precursor to serous carcinoma that originates in the distal fallopian tube
-
Lee, Y.; Miron, A.; Drapkin, R.; Nucci, M.R.; Medeiros, F.; Saleemuddin, A.; Garber, J.; Birch, C.; Mou, H.; Gordon, R.W.; Cramer, D.W.; McKeon, F.D.; Crum, C.P. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J. Pathol., 2007, 211(1), 26-35.
-
(2007)
J. Pathol
, vol.211
, Issue.1
, pp. 26-35
-
-
Lee, Y.1
Miron, A.2
Drapkin, R.3
Nucci, M.R.4
Medeiros, F.5
Saleemuddin, A.6
Garber, J.7
Birch, C.8
Mou, H.9
Gordon, R.W.10
Cramer, D.W.11
McKeon, F.D.12
Crum, C.P.13
-
14
-
-
65649098669
-
The fallopian tube: Primary site of most pelvic high-grade serous carcinomas
-
Salvador, S.; Gilks, B.; Kobel, M.; Huntsman, D.; Rosen, B.; Miller, D. The fallopian tube: primary site of most pelvic high-grade serous carcinomas. Int. J. Gynecol. Cancer, 2009, 19(1), 58-64.
-
(2009)
Int. J. Gynecol. Cancer
, vol.19
, Issue.1
, pp. 58-64
-
-
Salvador, S.1
Gilks, B.2
Kobel, M.3
Huntsman, D.4
Rosen, B.5
Miller, D.6
-
15
-
-
58349090850
-
Endometriosis
-
Bulun S.E. Endometriosis. N. Engl. J. Med., 2009, 360(3), 268-279.
-
(2009)
N. Engl. J. Med
, vol.360
, Issue.3
, pp. 268-279
-
-
Bulun, S.E.1
-
16
-
-
65649128979
-
Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma
-
Kuo, K.T.; Mao, T.L.; Jones, S.; Veras, E.; Ayhan, A.; Wang, T.L.; Glas, R.; Slamon, D.; Velculescu, V.E.; Kuman, R.J.; Shih, I.M. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am. J. Pathol., 2009, 174(5), 1597-1601.
-
(2009)
Am. J. Pathol
, vol.174
, Issue.5
, pp. 1597-1601
-
-
Kuo, K.T.1
Mao, T.L.2
Jones, S.3
Veras, E.4
Ayhan, A.5
Wang, T.L.6
Glas, R.7
Slamon, D.8
Velculescu, V.E.9
Kuman, R.J.10
Shih, I.M.11
-
17
-
-
33744466541
-
Antiangiogenic therapy: A universal chemosensitization strategy for cancer
-
Kerbel, R.S. Antiangiogenic therapy: a universal chemosensitization strategy for cancer. Science, 2006, 312(5777), 1171-1175.
-
(2006)
Science
, vol.312
, Issue.5777
, pp. 1171-1175
-
-
Kerbel, R.S.1
-
18
-
-
37849000515
-
Angiogenesis y neoplasias
-
Khosravi, P. Angiogenesis y neoplasias. An. Med. Interna, 2006, 23(8), 355-356.
-
(2006)
An. Med. Interna
, vol.23
, Issue.8
, pp. 355-356
-
-
Khosravi, P.1
-
19
-
-
0030952289
-
Mechanisms of angiogenesis
-
Risau, W. Mechanisms of angiogenesis. Nature, 1997, 386(6626), 671-674.
-
(1997)
Nature
, vol.386
, Issue.6626
, pp. 671-674
-
-
Risau, W.1
-
20
-
-
0034650802
-
Regulation of angiogenesis via vascular endothelial growth factor receptors
-
Veikkola, T.; Karkkainen, M.; Claesson-Welsh, L.; Alitalo, K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res., 2000, 60(2), 203-212.
-
(2000)
Cancer Res
, vol.60
, Issue.2
, pp. 203-212
-
-
Veikkola, T.1
Karkkainen, M.2
Claesson-Welsh, L.3
Alitalo, K.4
-
21
-
-
0037699954
-
The biology of VEGF and its receptors
-
Ferrara, N.; Gerber, H.P.; LeCouter, J. The biology of VEGF and its receptors. Nat. Med., 2003, 9(6), 669-676.
-
(2003)
Nat. Med
, vol.9
, Issue.6
, pp. 669-676
-
-
Ferrara, N.1
Gerber, H.P.2
Lecouter, J.3
-
22
-
-
37849050760
-
Tumoral angiogenesis: Review of the literature
-
Khosravi, P.; Fernandez, I. Tumoral angiogenesis: review of the literature. Cancer Invest. 2008, 26(1), 104-108.
-
(2008)
Cancer Invest
, vol.26
, Issue.1
, pp. 104-108
-
-
Khosravi, P.1
Fernandez, I.2
-
23
-
-
43249095919
-
Tumor angiogenesis
-
Kerbel, R.S. Tumor angiogenesis. N. Engl. J. Med., 2008, 358(19), 2039-2049.
-
(2008)
N. Engl. J. Med
, vol.358
, Issue.19
, pp. 2039-2049
-
-
Kerbel, R.S.1
-
24
-
-
0029929046
-
Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms
-
Abu-Jawdeh, G.M.; Faix, J.D.; Niloff, J.; Tognazzi, K.; Manseau, E.; Dvorak, H.F.; Brown, L.F. Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab. Invest. 1996, 74(6), 1105-1115.
-
(1996)
Lab. Invest
, vol.74
, Issue.6
, pp. 1105-1115
-
-
Abu-Jawdeh, G.M.1
Faix, J.D.2
Niloff, J.3
Tognazzi, K.4
Manseau, E.5
Dvorak, H.F.6
Brown, L.F.7
-
25
-
-
0030921126
-
The expression of vascular endothelial growth factor and transforming growth factor-ß associates with angiogenesis in epithelial ovarian cancer
-
Nakanishi, Y.; Kodama, J.; Yoshinouchi, M.; Tokumo, K.; Kamimura, S.; Okuda, H.; Kudo, T. The expression of vascular endothelial growth factor and transforming growth factor-ß associates with angiogenesis in epithelial ovarian cancer. Int. J. Gynecol. Pathol., 1997, 16(3), 256-262.
-
(1997)
Int. J. Gynecol. Pathol
, vol.16
, Issue.3
, pp. 256-262
-
-
Nakanishi, Y.1
Kodama, J.2
Yoshinouchi, M.3
Tokumo, K.4
Kamimura, S.5
Okuda, H.6
Kudo, T.7
-
26
-
-
33746721000
-
Immunolocalizations of VEGF, its receptors fl t-1, KDR and TGF-beta's in epithelial ovarian tumors
-
Inan, S.; Vatansever, S.; Celik-Ozenci, C.; Sanci, M.; Dicle, N.; Demir, R. Immunolocalizations of VEGF, its receptors fl t-1, KDR and TGF-beta's in epithelial ovarian tumors. Histol. Histopathol., 2006, 21(10),1055-1064.
-
(2006)
Histol. Histopathol
, vol.21
, Issue.10
, pp. 1055-1064
-
-
Inan, S.1
Vatansever, S.2
Celik-Ozenci, C.3
Sanci, M.4
Dicle, N.5
Demir, R.6
-
27
-
-
62549099008
-
The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer
-
Trinh, X.B.; Tjalma, W.A.; Vermeulen, P.B.; Van den Eynden, G.; Van der Auwera, I.; Van Laere, S.J.; Helleman, J.; Berns, E.M.; Dirix, L.Y.; van Dam, P.A. The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer. Br. J. Cancer., 2009, 100(6), 971-978.
-
(2009)
Br. J. Cancer
, vol.100
, Issue.6
, pp. 971-978
-
-
Trinh, X.B.1
Tjalma, W.A.2
Vermeulen, P.B.3
van den Eynden, G.4
van der Auwera, I.5
van Laere, S.J.6
Helleman, J.7
Berns, E.M.8
Dirix, L.Y.9
van Dam, P.A.10
-
28
-
-
4444324696
-
VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma
-
Chen, H.; Ye, D.; Xie, X.; Chen, B.; Lu, W. VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma. Gynecol. Oncol., 2004, 94(3), 630-635.
-
(2004)
Gynecol. Oncol
, vol.94
, Issue.3
, pp. 630-635
-
-
Chen, H.1
Ye, D.2
Xie, X.3
Chen, B.4
Lu, W.5
-
29
-
-
58149202145
-
Angiogenesis-related gene expression profile with independent prognostic value in advanced ovarian carcinoma
-
Mendiola, M.; Barriuso, J.; Redondo, A. Angiogenesis-related gene expression profile with independent prognostic value in advanced ovarian carcinoma. PLoS. One, 2008, 3, e4051.
-
(2008)
PLoS. One
, vol.3
-
-
Mendiola, M.1
Barriuso, J.2
Redondo, A.3
-
30
-
-
33845490014
-
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
-
Sandler, A.; Gray, R.; Perry, M.C.; Brahmer, J.; Schiller, J.H.; Dowlati, A.; Lilenbaum, R.; Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med., 2006, 355(24), 2542-2550.
-
(2006)
N. Engl. J. Med
, vol.355
, Issue.24
, pp. 2542-2550
-
-
Sandler, A.1
Gray, R.2
Perry, M.C.3
Brahmer, J.4
Schiller, J.H.5
Dowlati, A.6
Lilenbaum, R.7
Johnson, D.H.8
-
31
-
-
37549040613
-
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
-
Miller, K.; Wang, M.; Gralow, J.; Dickler, M.; Cobleigh, M.; Perez, E.A.; Shenkier, T.; Cella, D.; Davidson, N.E. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med., 2007, 357(26), 2666-2676.
-
(2007)
N. Engl. J. Med
, vol.357
, Issue.26
, pp. 2666-2676
-
-
Miller, K.1
Wang, M.2
Gralow, J.3
Dickler, M.4
Cobleigh, M.5
Perez, E.A.6
Shenkier, T.7
Cella, D.8
Davidson, N.E.9
-
32
-
-
2542561964
-
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
-
Hurwitz, H.; Fehrenbacher, L.; Novotny, W.; Cartwright, T.; Hainsworth, J.; Heim, W.; Berlin, J.; Baron, A.; Griffing, S.; Holmgren, E.; Ferrara, N.; Fyfe, G.; Rogers, B.; Ross, R.; Kabbinavar, F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med., 2004, 350(23), 2335-2342.
-
(2004)
N. Engl. J. Med
, vol.350
, Issue.23
, pp. 2335-2342
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Novotny, W.3
Cartwright, T.4
Hainsworth, J.5
Heim, W.6
Berlin, J.7
Baron, A.8
Griffing, S.9
Holmgren, E.10
Ferrara, N.11
Fyfe, G.12
Rogers, B.13
Ross, R.14
Kabbinavar, F.15
-
33
-
-
37349080670
-
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial
-
Escudier, B.; Pluzanska, A.; Koralewski, P.; Ravaud, A.; Bracarda, S.; Szczylik, C.; Chevreau, C.; Filipek, M.; Melichar, B.; Bajetta, E.; Gorbunova, V.; Bay, J.O.; Bodrogi, I.; Jagiello-Gruszfeld, A.; Moore, N. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet, 2007, 370(9605), 2103-2111.
-
(2007)
Lancet
, vol.370
, Issue.9605
, pp. 2103-2111
-
-
Escudier, B.1
Pluzanska, A.2
Koralewski, P.3
Ravaud, A.4
Bracarda, S.5
Szczylik, C.6
Chevreau, C.7
Filipek, M.8
Melichar, B.9
Bajetta, E.10
Gorbunova, V.11
Bay, J.O.12
Bodrogi, I.13
Jagiello-Gruszfeld, A.14
Moore, N.15
-
34
-
-
36849019301
-
Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group Study
-
Burger, R.A.; Sill, M.W.; Monk, B.J.; Greer, B.E.; Sorosky, J.I. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol., 2007, 25(33), 5165-5171.
-
(2007)
J. Clin. Oncol
, vol.25
, Issue.33
, pp. 5165-5171
-
-
Burger, R.A.1
Sill, M.W.2
Monk, B.J.3
Greer, B.E.4
Sorosky, J.I.5
-
35
-
-
36849056497
-
Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer
-
Cannistra, S.A.; Matulonis, U.A.; Penson, R.T.; Hambleton, J.; Dupont, J.; Mackey, H.; Douglas, J.; Burger, R.A.; Armstrong, D.; Wenham, R.; McGuire, W. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J. Clin. Oncol., 2007, 25(33), 5180-5186.
-
(2007)
J. Clin. Oncol
, vol.25
, Issue.33
, pp. 5180-5186
-
-
Cannistra, S.A.1
Matulonis, U.A.2
Penson, R.T.3
Hambleton, J.4
Dupont, J.5
Mackey, H.6
Douglas, J.7
Burger, R.A.8
Armstrong, D.9
Wenham, R.10
McGuire, W.11
-
36
-
-
34447298651
-
A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer
-
Micha, J.P.; Goldstein, B.H.; Rettenmaier, M.A.; Genesen, M.; Graham, C.; Bader, K.; Lopez, K.L.; Nickle, M.; Brown, J.V. A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. Int. J. Gynecol. Cancer, 2007, 17(4), 771-776.
-
(2007)
Int. J. Gynecol. Cancer
, vol.17
, Issue.4
, pp. 771-776
-
-
Micha, J.P.1
Goldstein, B.H.2
Rettenmaier, M.A.3
Genesen, M.4
Graham, C.5
Bader, K.6
Lopez, K.L.7
Nickle, M.8
Brown, J.V.9
-
37
-
-
73949092398
-
Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors
-
Penson, R.T.; Dizon, D.S.; Cannistra, S.A.; Roche, M.R.; Krasner, C.N.; Berlin, S.T.; Horowitz, N.S.; Disilvestro, P.A.; Matulonis, U.A.; Lee, H.; King, M.A.; Campos, S.M. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J. Clin. Oncol., 2010, 28(1), 154-159.
-
(2010)
J. Clin. Oncol
, vol.28
, Issue.1
, pp. 154-159
-
-
Penson, R.T.1
Dizon, D.S.2
Cannistra, S.A.3
Roche, M.R.4
Krasner, C.N.5
Berlin, S.T.6
Horowitz, N.S.7
Disilvestro, P.A.8
Matulonis, U.A.9
Lee, H.10
King, M.A.11
Campos, S.M.12
-
38
-
-
77954499682
-
Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or Fallopian tube cancer (FTC): A Gynecologic Oncology Group study
-
Burger, R.A.; Brady, M.L.; Bookman, M.A.; Walker, J.L.; Homesley, H. D.; Fowler, J.; Monk, B. J.; Greer, B. E.; Boente, M.; Liang, S. X. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or Fallopian tube cancer (FTC): a Gynecologic Oncology Group study. J. Clin. Oncol., 2010, 28(18s), LBA1.
-
(2010)
J. Clin. Oncol
, vol.28
, Issue.18 s
-
-
Burger, R.A.1
Brady, M.L.2
Bookman, M.A.3
Walker, J.L.4
Homesley, H.D.5
Fowler, J.6
Monk, B.J.7
Greer, B.E.8
Boente, M.9
Liang, S.X.10
-
39
-
-
78650450402
-
ICON-7: A phase III Gynaecologic Cancer InterGroup (GCIG) trial of adding bevacizumab to standard chemotherapy in women with newly diagnosed epithelial ovarian, primary peritoneal or fallopian tube cancer
-
Perren, T.; Swart, A.M.; Pfisterer, J.; Ledermann, J.; Lortholary, A.; Kristensen, G.; Carey, M.; Beale, P.; Cervantes, A.; Oza, A. ICON-7: A phase III Gynaecologic Cancer InterGroup (GCIG) trial of adding bevacizumab to standard chemotherapy in women with newly diagnosed epithelial ovarian, primary peritoneal or fallopian tube cancer. Ann. Oncol., 2010, 21(8s), viii1-viii12.
-
(2010)
Ann. Oncol
, vol.21
, Issue.8 s
-
-
Perren, T.1
Swart, A.M.2
Pfisterer, J.3
Ledermann, J.4
Lortholary, A.5
Kristensen, G.6
Carey, M.7
Beale, P.8
Cervantes, A.9
Oza, A.10
-
40
-
-
80054003628
-
Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer
-
Kristensen, G.; Perren, T.; Qian, W. Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. J. Clin. Oncol., 2011, 29, LBA5006.
-
(2011)
J. Clin. Oncol
, vol.29
-
-
Kristensen, G.1
Perren, T.2
Qian, W.3
-
41
-
-
77956799700
-
Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: A study of the princess margaret hospital phase II consortium
-
Welch, S.A.; Hirte, H.W.; Elit, L.; Schilder, R.J.; Wang, L.; MacAlpine, K.; Wright, J.J.; Oza, A.M. Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: A study of the princess margaret hospital phase II consortium. Int. J. Gynecol. Cancer, 2010, 20(5), 787-793.
-
(2010)
Int. J. Gynecol. Cancer
, vol.20
, Issue.5
, pp. 787-793
-
-
Welch, S.A.1
Hirte, H.W.2
Elit, L.3
Schilder, R.J.4
Wang, L.5
Macalpine, K.6
Wright, J.J.7
Oza, A.M.8
-
42
-
-
79952814774
-
A randomized phase II study of paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer
-
Hainsworth, J.D.; Numnum, T.M.; Rao, G.G. A randomized phase II study of paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer. J. Clin. Oncol., 2010, 28(18s), TPS257.
-
(2010)
J. Clin. Oncol
, vol.28
, Issue.18 s
-
-
Hainsworth, J.D.1
Numnum, T.M.2
Rao, G.G.3
-
43
-
-
77956649079
-
A Phase II open-label study evaluating pazopanib in patients with recurrent ovarian cancer
-
Friedlander, M.; Hancock, K.C.; Rischin, D.; Messing, M.J.; Stringer, C.A.; Matthys, G.M.; Ma, B.; Hodge, J.P.; Lager, J.J. A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol. Oncol., 2010, 119(1),32-37.
-
(2010)
Gynecol. Oncol
, vol.119
, Issue.1
, pp. 32-37
-
-
Friedlander, M.1
Hancock, K.C.2
Rischin, D.3
Messing, M.J.4
Stringer, C.A.5
Matthys, G.M.6
Ma, B.7
Hodge, J.P.8
Lager, J.J.9
-
44
-
-
73949123481
-
Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer
-
Matulonis, U.A.; Berlin, S.; Ivy, P.; Tyburski, K.; Krasner, C.; Zarwan, C.; Berkenblit, A.; Campos, S.; Horowitz, N.; Cannistra, S.A.; Lee, H.; Lee, J.; Roche, M.; Hill, M.; Whalen, C.; Sullivan, L.; Tran, C.; Humphreys, B.D.; Penson, R.T. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J. Clin. Oncol., 2009, 273), 5601-5606.
-
(2009)
J. Clin. Oncol
, vol.27
, pp. 5601-5606
-
-
Matulonis, U.A.1
Berlin, S.2
Ivy, P.3
Tyburski, K.4
Krasner, C.5
Zarwan, C.6
Berkenblit, A.7
Campos, S.8
Horowitz, N.9
Cannistra, S.A.10
Lee, H.11
Lee, J.12
Roche, M.13
Hill, M.14
Whalen, C.15
Sullivan, L.16
Tran, C.17
Humphreys, B.D.18
Penson, R.T.19
-
45
-
-
58149219264
-
A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: Final results of a PMH, Chicago and California consortia trial
-
Hirte, H.W.; Vidal, L.; Fleming, G.F. A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: Final results of a PMH, Chicago and California consortia trial. J. Clin. Oncol., 2008, 26, 5521.
-
(2008)
J. Clin. Oncol
, vol.26
, pp. 5521
-
-
Hirte, H.W.1
Vidal, L.2
Fleming, G.F.3
-
46
-
-
68449095803
-
A randomized phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer (OC)
-
Ledermann, J.A.; Rustin, G.J.; Hackshaw, A. A randomized phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer (OC). J. Clin. Oncol., 2009, 27(15s), 5501.
-
(2009)
J. Clin. Oncol
, vol.27
, Issue.15 s
, pp. 5501
-
-
Ledermann, J.A.1
Rustin, G.J.2
Hackshaw, A.3
-
47
-
-
79251585977
-
A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: An NCIC Clinical Trials Group Study
-
Biagi, J.J.; Oza, A.M.; Chalchal, H.I.; Grimshaw, R.; Ellard, S.L.; Lee, U.; Hirte, H.; Sederias, J.; Ivy, S.P.; Eisenhauer, E.A. A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. Ann. Oncol., 2011, 22(2), 335-340.
-
(2011)
Ann. Oncol
, vol.22
, Issue.2
, pp. 335-340
-
-
Biagi, J.J.1
Oza, A.M.2
Chalchal, H.I.3
Grimshaw, R.4
Ellard, S.L.5
Lee, U.6
Hirte, H.7
Sederias, J.8
Ivy, S.P.9
Eisenhauer, E.A.10
-
48
-
-
46749111576
-
AVE 0005, AVE 005, AVE0005, VEGF Trap -Regeneron, VEGF Trap (R1R2), VEGF Trap-Eye
-
Aflibercept
-
Aflibercept: AVE 0005, AVE 005, AVE0005, VEGF Trap -Regeneron, VEGF Trap (R1R2), VEGF Trap-Eye. Drug. R. D., 2008, 9(4), 261-269.
-
(2008)
Drug. R. D
, vol.9
, Issue.4
, pp. 261-269
-
-
-
49
-
-
79958828731
-
A randomised, double-blind, placebo-controlled phase 2 study of AMG 386 plus weekly paclitaxel in patients (pts) with advanced ovarian cancer
-
Vergote, I.B.; Oza, A.M.; Hansen, V.L. A randomised, double-blind, placebo-controlled phase 2 study of AMG 386 plus weekly paclitaxel in patients (pts) with advanced ovarian cancer. Ann. Oncol., 2010, 21(8s), 975PD.
-
(2010)
Ann. Oncol
, vol.21
, Issue.8 s
-
-
Vergote, I.B.1
Oza, A.M.2
Hansen, V.L.3
-
50
-
-
77954522477
-
Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients (pts) with recurrent ovarian carcinoma
-
Karlan, B.Y.; Oza, A.M.; Hansen, V.L.; Richardson, G.E.; Provencher, D.M.; Ghatage, P.; Tassoudji, M.; Stepan, D.E.; Weinreich, D.M.; Vergote, I. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients (pts) with recurrent ovarian carcinoma. J. Clin. Oncol., 2010, 28(15s), 5000.
-
(2010)
J. Clin. Oncol
, vol.28
, Issue.15 s
, pp. 5000
-
-
Karlan, B.Y.1
Oza, A.M.2
Hansen, V.L.3
Richardson, G.E.4
Provencher, D.M.5
Ghatage, P.6
Tassoudji, M.7
Stepan, D.E.8
Weinreich, D.M.9
Vergote, I.10
|